# US 7,078,236 B2 · Methods of inducing ovulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,078,236 B2
- Document ID: US7078236B2
- Status: Granted
- Kind: B2
- Application number: 11/169,183
- Filed: 2005-06-28
- Published: 2006-01-05
- Granted: 2006-07-18
- Earliest claimed: 2000-08-11
- Assignees: Applied Research Systems ARS Holding N.V.
- Inventors: Stephen Palmer; Sean McKenna; Mark Tepper; Aliza Eshkol; Michael C. MacNamee
- Web page: https://patentgrep.com/patent/US7078236B2

## CPC

- A61K 38/24: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A61K 31/275: Nitriles; Isonitriles
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

## Claims

### Claim 1

A method of combined treatment for stimulating follicular development and ovulation induction in a female host comprising:
(a) administering an agent which increases follicle stimulating hormone concentrations in the host during the follicular phase of the host's ovulatory cycle; and
(b) administering an inhibitor of a phosphodiesterase 4 isoform to the host prior to the luteal phase of the host's ovulatory cycle.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agent is follicle stimulating hormone.

### Claim 3 (depends on 1)

The method of claim 1 wherein luteinizing hormone is also administered to the host to induce ovulation prior to the luteal phase of the host's ovulatory cycle.

### Claim 4 (depends on 3)

The method of claim 3, wherein the inhibitor of a phosphodiesterase 4 isoform and luteinizing hormone are coadministered.

### Claim 5 (depends on 4)

The method of claim 4, wherein the coadministration is sequential.

### Claim 6 (depends on 4)

The method of claim 4, wherein the coadministration is simultaneous.

### Claim 7 (depends on 4)

The method of claim 4, wherein the inhibitor of a phosphodiesterase 4 isoform and luteinizing hormone are administered by the same mode of delivery.

### Claim 8 (depends on 4)

The method of claim 4, wherein the inhibitor of a phosphodiesterase 4 isoform and luteinizing hormone are administered by different modes of delivery.

### Claim 9 (depends on 1)

The method of claim 1, wherein luteinizing hormone is also administered at a dose lower than the amount of luteinizing hormone to induce ovulation in the same host in existing regimens prior to the luteal phase of the host's ovulatory cycle.

### Claim 10 (depends on 1)

The method of claim 1, wherein chorionic gonadotropin is also administered to the host to induce ovulation prior to the luteal phase of the host's ovulatory cycle.

### Claim 11 (depends on 10)

The method of claim 10, wherein the inhibitor of a phosphodiesterase 4 isoform and chorionic gonadotropin are coadministered.

### Claim 12 (depends on 11)

The method of claim 11, wherein the coadministration is sequential.

### Claim 13 (depends on 11)

The method of claim 11, wherein the coadministration is simultaneous.

### Claim 14 (depends on 11)

The method of claim 11, wherein the inhibitor of a phosphodiesterase 4 isoform and luteinizing hormone are administered by the same mode of delivery.

### Claim 15 (depends on 11)

The method of claim 11, wherein the inhibitor of a phosphodiesterase 4 isoform and luteinizing hormone are administered by different modes of delivery.

### Claim 16 (depends on 1)

The method of claim 1, wherein chorionic gonadotropin is also administered at reduced a dose lower than the amount of chorionic gonadotropin to induce ovulation in the same host in existing regimens prior to the luteal phase of the host's ovulatory cycle.

### Claim 17 (depends on 1)

The method of claim 1 wherein the inhibitor of a phosphodiesterase 4 isoform is administered orally.